In the present invention, there is disclosed a piperazinylcarbonyl quinoline or piperazinylcarbonyl isoquinoline derivative of the general formula I, in which Re1 represents an optionally Hal-substituted phenyl or naphthyl group, Re2 represents a quinoline or isoquinoline group, alk denotes an alkylene group containing 2 to 6 carbon atoms, Hal denotes a fluorine, chlorine, bromine or iodine atom, and physiologically acceptable salts and solvates thereof. There is further disclosed a process for preparing such derivatives as well as their use and pharmaceutical compositions containing them. The above-described derivatives are inhibitors of 5-HTi2A receptor and they san be therefore used for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders, such as bulimia, anorexia, nervosa, premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder.
Piperazinylcarbonyl quinoline or piperazinylcarbonyl isoquinoline derivative, process of its preparation, its use and pharmaceutical preparation in which the derivative is comprised